Ulcerative proctitis: a review of pharmacotherapy and management

Bibliography

• Lakatos PL, Fischer S, Lakatos L, et al. Current concept on the pathogenesis of IBD: crosstalk between genetic and microbial factors. Pathogenic bacteria, altered bacterial sensing or changes in mucosal integrity take “toll”? World J Gastroenterol 2006;12:1829-40
   PubMed Web of Science ®Google Scholar
• Lakatos PL. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J Gastroenterol 2006;12:6102-8
   PubMed Web of Science ®Google Scholar
• Shivananda S, Lennard-Jones J, Logan R, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European collaborative study on inflammatory bowel disease (EC-IBD). Gut 1996;39:690-7
   PubMed Web of Science ®Google Scholar
• Lakatos L, Mester G, Erdelyi Z, et al. Striking elevation in the incidence and prevalence of inflammatory bowel disease in a province of Western Hungary between 1977-2001. World J Gastroenterol 2004;10:404-9
   PubMed Web of Science ®Google Scholar
• Jess T, Riis L, Vind I, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis 2007;13:481-9
   PubMed Web of Science ®Google Scholar
• Moum B, Ekbom A, Vatn MH, et al. Change in extent of colonoscopic and histological involvement in ulcerative colitis over time. Am J Gastroenterol 1999;94:1564-9
   PubMed Web of Science ®Google Scholar
• Ayres RC, Gillen CD, Walmsley RS, et al. Progression in ulcerative proctosigmoiditis: incidence and factors influencing progression. Eur J Gastroenterol Hepatol 1996;8:555-8
   PubMedGoogle Scholar
• Langholz E, Munkholm P, Davidsen M, et al. Changes in extent of ulcerative colitis. Scand J Gastroenterol 1996;31:260-6
   PubMed Web of Science ®Google Scholar
• Henriksen M, Jahnsen J, Lygren I, et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis 2006;12:543-50
   PubMed Web of Science ®Google Scholar
• Pica R, Paoluzi OA, Iacopini F, et al. Oral mesalazine (5-ASA) treatment may protect against proximal extension of mucosal inflammation in ulcerative proctitis. Inflamm Bowel Dis 2004;10:731-6
   PubMed Web of Science ®Google Scholar
• Regueiro M, Loftus EV Jr, Steinhart H, et al. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis 2006;12:979-94
   PubMed Web of Science ®Google Scholar
• Nilsson A. Optimizing management of distal ulcerative colitis. Scand J Gastroenterol 2006;41:511-23
   PubMed Web of Science ®Google Scholar
• Cohen RD, Woseth DM, Thisted RA, et al. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 2000;95:1263-76
   PubMed Web of Science ®Google Scholar
• Su C, Lewis JD, Goldberg B, et al. A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterol 2007;132:516-26
   PubMed Web of Science ®Google Scholar
• Van Bodegraven AA, Boer RO, Lourens J, et al. Distribution of mesalazine enemas in active and quiescent ulcerative colitis. Aliment Pharmacol Ther 1996;10:327-32
   PubMedGoogle Scholar
• Cerveny P, Bortlik M, Kubena A, et al. Non-adherence in inflammatory bowel disease-results of factor analysis. Inflamm Bowel Dis 2007;13:1244-9
   PubMed Web of Science ®Google Scholar
• Kane S, Cohen RD, Aikens JE, et al. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001;96:2929-33
   PubMed Web of Science ®Google Scholar
• Marshall JK, Irvine EJ. Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis. Aliment Pharmacol Ther 1995;9:293-300
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizello F, Morselli C, et al. Review article: aminosalicylates for distal colitis. Aliment Pharmacol Ther 2006;24(Suppl 3):41-4
   PubMedGoogle Scholar
• Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatment in ulcerative colitis: a meta-analysis. Gut 1997;40:775-81
   PubMed Web of Science ®Google Scholar
• Marshall JK, Irvine EJ. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis. Am J Gastroenterol 2000;95:1628-36
   PubMed Web of Science ®Google Scholar
• Lemann M, Galian A, Rutgeerts P, et al. Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis. Aliment Pharmacol Ther 1995;9:557-2
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Robinson M, Pruitt R, et al. Budesonide enema for the treatment of active distal ulcerative colitis and proctitis: a dose ranging study. Gastroenterology 1998;115:525-32
   PubMed Web of Science ®Google Scholar
• Angus P, Snook JA, Reid M, Jewell DP. Oral fluticasone propionate in active distal ulcerative colitis. Gut 1992;33:711-4
   PubMedGoogle Scholar
• Campieri M, Cottone M, Miglio F, et al. Beclomethasone dipropionate enemas versus prednisolone sodium phosphate in the treatment of distal ulcerative colitis. Aliment Pharmacol Ther 1998;12:361-6
   PubMed Web of Science ®Google Scholar
• Biancone L, Gionchetti P, Del Vecchio Blanco G, et al. Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study. Dig Liver Dis 2007;39:329-37
   PubMedGoogle Scholar
• Manguso F, Balzano A. Meta-analysis: the efficacy of rectal beclomethasone dipropionate vs. 5-aminosalicylic acid in mild to moderate distal ulcerative colitis. Aliment Pharmacol Ther 2007;26:21-9
   PubMed Web of Science ®Google Scholar
• Bergman R, Parkes M. Systematic review: the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther 2006;23:841-55
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Venturi A, et al. Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. Dis Colon Rectum 1998;41:93-7
   PubMed Web of Science ®Google Scholar
• Hebden JM, Blackshaw PE, Perkins AC, et al. Limited exposure of the healthy distal colon to orally-dosed formulation is further exaggerated in active leftsided ulcerative colitis. Aliment Pharmacol Ther 2000;14:155-61
   PubMed Web of Science ®Google Scholar
• Safdi M, Demicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997;92:1867-71
   PubMed Web of Science ®Google Scholar
• Frieri G, Pimpo MT, Palombo GC, et al. Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs oral plus topical treatment. Aliment Pharmacol Ther 1999;13:1413-7
   PubMed Web of Science ®Google Scholar
• Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006;2:CD000543
   Google Scholar
• Desreumaux P, Ghosh S. Review article: mode of action and delivery of 5-aminosalicylic acid – new evidence. Aliment Pharmacol Ther 2006;24(Suppl 1):2-9
   PubMed Web of Science ®Google Scholar
• Dignass A, Vermeire S, Adamek H, et al. Improved remission rates from once- versus twice-daily mesalazine (Pentasa®) granules for the maintenance of remission in ulcerative colitis: results from a multinational randomised controlled trial. Gut 2007;56:OP-G-378
   Google Scholar
• Sandborn WJ, Kamm MA, Lichtenstein GR, et al. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther 2007;26:205-15
   PubMed Web of Science ®Google Scholar
• Mulder CJ, Fockens P, Meijer JW, et al. Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. Eur J Gastroenterol Hepatol 1996;8:549-53
   PubMed Web of Science ®Google Scholar
• Misiewicz JJ, Lennard-Jones JE, Connell AM, et al. Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis. Lancet 1965;1:185-8
   Web of Science ®Google Scholar
• Banerjee S, Peppercorn MA. Inflammatory bowel disease: medical therapy for specific clinical presentations. Gastroenterol Clin North Am 2002;31:185-202
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Good LI, Goodman MW, et al. Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis. Am J Gastroenterol 2000;95:1749-54
   PubMed Web of Science ®Google Scholar
• Mantzaris GJ, Hatzis A, Petraki K, et al. Intermittent therapy with high-dose aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis. Dis Colon Rectum 1994;37:58-62
   PubMedGoogle Scholar
• Marteau P, Crand J, Foucault M, et al. Use of mesalazine slow-release suppositories 1 g three times per week to maintain remission in ulcerative proctitis: a randomized double blind placebo controlled multicentre study. Gut 1998;42:195-9
   PubMed Web of Science ®Google Scholar
• D'Albasio G, Pacini F, Cammari E, et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J Gastroenterol 1997;92:1143-7
   PubMed Web of Science ®Google Scholar
• Lennard-Jones JE, Misiewicz JJ, Connell AM, et al. Prednisone as maintenance treatment for ulcerative colitis in remission. Lancet 1965;191:188-9
   Google Scholar
• Kirk AP, Lennard-Jones JE. Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J 1982;284:1291-2
   PubMed Web of Science ®Google Scholar
• Hawthorne A, Logan R, Hawkey C, et al. Randomized controlled trial of azathioprine withdrawal in ulcerative colitis. Br Med J 1992;305:20-2
   PubMed Web of Science ®Google Scholar
• Ardizzone S, Maconi G, Russo A, et al. Randomized controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid-dependent ulcerative colitis. Gut 2006;55:47-53
   PubMed Web of Science ®Google Scholar
• Kruis W, Schutz E, Fric P, et al. Double-blind comparison of an oral Escherichia coli preparation and mesalamine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997;11:853-8
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Morselli C, et al. Review article: problematic proctitis and distal colitis. Aliment Pharmacol Ther 2004;20(Suppl 4):93-6
   PubMedGoogle Scholar
• Griffin MG, Miner PB. Review article: refractory distal colitis: explanations and options. Aliment Pharmacol Ther 1996;10:39-48
   PubMedGoogle Scholar
• Järnerot G, Rolny P, Sandberg-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985;89:1005-13
   PubMed Web of Science ®Google Scholar
• Truelove SC, Witts LJ. Cortisone in ulcerative colitis: preliminary report on a therapeutic trial. Br Med J 1954;2:375-8
   PubMed Web of Science ®Google Scholar
• Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J 1955;2:1041-8
   PubMed Web of Science ®Google Scholar
• Lichtiger S, Present D, Kornbluth A, et al. Cyclosporin in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-5
   PubMed Web of Science ®Google Scholar
• D'Haens G, Lemmens L, Geboes K, et al. Intravenous cyclosporine versus intravenous corticosteroids as a single therapy for severe attacks of ulcerative colitis. Gastroenterology 2000;120:1323-9
   Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan B, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;233:2462-73
   Google Scholar
• Järnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128:1805-11
   PubMed Web of Science ®Google Scholar
• Jakobovits SL, Jewell DP, Travis SPL. Infliximab 5 mg/kg induction (0, 2, and 6 weeks) followed by maintenance therapy (every 8 weeks) offers the newest treatment option for moderately to severely active UC failing 5-ASAs and corticosteroids. Aliment Pharmacol Ther 2007;25:1055-60
   PubMed Web of Science ®Google Scholar
• Lakatos L, Lakatos PL. Management of inflammatory bowel diseases in Eastern Europe. Postgrad Med J 2006;82:270-3
   PubMedGoogle Scholar
• Hoie O, Wolters FL, Riis L, et al. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology 2007;132:507-15
   PubMed Web of Science ®Google Scholar
• Brunel M, Penne C, Tiret E, et al. Restorative proctocolectomy for distal ulcerative colitis. Gut 1999;45:542-5
   PubMedGoogle Scholar
• Eaden JA, Abrams K, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526-35
   PubMed Web of Science ®Google Scholar
• Loftus EV. Epidemiology and risk factors for colorectal dysplasia and cancer in ulcerative colitis. Gastroent Clin North Am 2006;35:517-31
   PubMed Web of Science ®Google Scholar
• Rubin DT, Lashner BA. Will a 5-ASA a day keep the cancer (and dysplasia) away? Am J Gastroenterol 2005;100:1354-6
   PubMed Web of Science ®Google Scholar